<DOC>
	<DOC>NCT01470144</DOC>
	<brief_summary>This is an open-label, nonrandomized extension to study AC-066A301. The study will assess safety and tolerability of ACT-385781A while providing a means for continuing treatment after ending participation in study AC-066A301.</brief_summary>
	<brief_title>Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>1. Signed informed consent prior to initiation of any studymandated procedure 2. Patients who completed participation in study AC066A301 3. Patients who have not obtained access for commercial EFI at the time of ending participation in study AC066A301 1. Patients who prematurely discontinued study drug in study AC066A301 2. Patients for whom continued treatment with EFI is no longer considered appropriate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>